Salix Pharmaceuticals Inc

General

Total Cases64

Active Cases14

Patents43

CourtsD. New Jersey D. Delaware N.D. West Virginia

TypeOperating Company

Elite Ratings

--

salix-pharmaceuticals

salix-pharmaceuticals

Ratings

Experience

Grade

Trend

DCT

L5

A

PTAB

L5

D

CAFC

L4

E

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
09/13/24	Curia IP Holdings LLC v. Salix Pharmaceuticals Ltd 2:21-CV-19293 ( D. NJ )	Letter from E. Abraham to Judge Almonte re 249 Text Order,,,. (ABRAHAM, ERIC) (Entered: 09/13/2024)
09/13/24	Curia IP Holdings LLC v. Salix Pharmaceuticals Ltd 2:21-CV-19293 ( D. NJ )	Letter from E. Abraham to Judge Almonte re 249 Text Order,,,. (ABRAHAM, ERIC) (Entered: 09/13/2024)
09/12/24	Bausch Health Ireland Ltd v. Mylan Laboratories Ltd 1:22-CV-00020 ( N.D. WV )	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. Reply Expert Report of Dr. Graham Buckton, Ph.D. Regarding Defendants In re Cellect Defense; and Reply Expert Report of Dr. Zhaohui Sunny Zhou, Ph.D., Regarding U.S. Patent No. 11,834,521. (Copland, Gordon) (Entered: 09/12/2024)
09/10/24	Bausch Health Ireland Ltd v. Mylan Laboratories Ltd 1:22-CV-00020 ( N.D. WV )	CERTIFICATE OF SERVICE by Bausch Health Ireland Limited, Salix Pharmaceuticals, Inc certifying service of Plaintiff's Reply Expert Report of Robert O. Williams, III, Ph.D., on Infringement and Objective Evidence of Nonobviousness Regarding U.S. Patent No. 11,834,521 and Reply Expert Report of Stephen G. Davies, D. Phil, on Infringement and Objective Evidence of Nonobviousness Regarding U.S. Patent No. 11,834,521. (Higginbotham, Daniel) (Entered: 09/10/2024) CERTIFICATE OF SERVICE by Bausch Health Ireland Limited, Salix Pharmaceuticals, Inc certifying service of Plaintiff's Reply Expert Report of Robert O. Williams, III, Ph.D., on Infringement and Objective Evidence of Nonobviousness Regarding U.S. Patent No. 11,834,521 and Reply Expert Report of Stephen G. Davies, D. Phil, on Infringement and Objective Evidence of Nonobviousness Regarding U.S. Patent No. 11,834,521. (Higginbotham, Daniel) (Entered: 09/10/2024)
09/09/24	Curia IP Holdings LLC v. Salix Pharmaceuticals Ltd 2:21-CV-19293 ( D. NJ )	TEXT ORDER: A status conference is scheduled for October 4, 2024, at 2:00 p.m. For the conference, please dial 973-437-5535 and enter Phone conference ID: 879 007 788#. No later than September 27, 2024, the parties shall file a joint letter not to exceed five (5) pages summarizing the status of the case. To the extent the parties wish to raise a discovery dispute, they shall do so consistent with the Court's [Case Management Order]. So Ordered by Magistrate Judge Jose R. Almonte on 9/5/2024. (akw, ) (Entered: 09/09/2024) TEXT ORDER: A status conference is scheduled for October 4, 2024, at 2:00 p.m. For the conference, please dial 973-437-5535 and enter Phone conference ID: 879 007 788#. No later than September 27, 2024, the parties shall file a joint letter not to exceed five (5) pages summarizing the status of the case. To the extent the parties wish to raise a discovery dispute, they shall do so consistent with the Court's [Case Management Order]. So Ordered by Magistrate Judge Jose R. Almonte on 9/5/2024. (akw, ) (Entered: 09/09/2024)
09/09/24	Curia IP Holdings LLC v. Salix Pharmaceuticals Ltd 2:21-CV-19293 ( D. NJ )	TEXT ORDER: A status conference is scheduled for October 4, 2024, at 2:00 p.m. For the conference, please dial 973-437-5535 and enter Phone conference ID: 879 007 788#. No later than September 27, 2024, the parties shall file a joint letter not to exceed five (5) pages summarizing the status of the case. To the extent the parties wish to raise a discovery dispute, they shall do so consistent with the Court's [Case Management Order]. So Ordered by Magistrate Judge Jose R. Almonte on 9/5/2024. (akw, ) (Entered: 09/09/2024) TEXT ORDER: A status conference is scheduled for October 4, 2024, at 2:00 p.m. For the conference, please dial 973-437-5535 and enter Phone conference ID: 879 007 788#. No later than September 27, 2024, the parties shall file a joint letter not to exceed five (5) pages summarizing the status of the case. To the extent the parties wish to raise a discovery dispute, they shall do so consistent with the Court's [Case Management Order]. So Ordered by Magistrate Judge Jose R. Almonte on 9/5/2024. (akw, ) (Entered: 09/09/2024)
09/05/24	Curia IP Holdings LLC v. Salix Pharmaceuticals Ltd 2:21-CV-19293 ( D. NJ )	LETTER ORDER granting [253] Joint Request for a two (2) week extension of the parties' deadline to file a joint motion to seal the Court's August 26, 2024 Opinion (ECF No. 247) from 9/25/2024 to 10/9/2024. Signed by Magistrate Judge Jose R. Almonte on 9/5/2024. (dam) (Entered: 09/05/2024)
09/05/24	Curia IP Holdings LLC v. Salix Pharmaceuticals Ltd 2:21-CV-19293 ( D. NJ )	LETTER ORDER granting [253] Joint Request for a two (2) week extension of the parties' deadline to file a joint motion to seal the Court's August 26, 2024 Opinion (ECF No. 247) from 9/25/2024 to 10/9/2024. Signed by Magistrate Judge Jose R. Almonte on 9/5/2024. (dam) (Entered: 09/05/2024)
09/04/24	Curia IP Holdings LLC v. Salix Pharmaceuticals Ltd 2:21-CV-19293 ( D. NJ )	Letter from William P. Deni, Jr. to the Honorable Jose R. Almonte, U.S.M.J. re: extension request. (DENI, WILLIAM) (Entered: 09/04/2024)
09/04/24	Curia IP Holdings LLC v. Salix Pharmaceuticals Ltd 2:21-CV-19293 ( D. NJ )	Letter from William P. Deni, Jr. to the Honorable Jose R. Almonte, U.S.M.J. re: extension request. (DENI, WILLIAM) (Entered: 09/04/2024)